HELIOS Klinikum Duisburg GmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The department is advancing care for blood‑related malignancies by testing innovative drug combinations and maintenance strategies aimed at deeper remission and longer survival.
- Combination of a tyrosine‑kinase inhibitor, chemotherapy and blinatumomab for Philadelphia‑positive acute lymphoblastic leukemia
- Iberdomide plus isatuximab to increase bone‑marrow MRD‑negativity rates in multiple myeloma
- Subcutaneous versus intravenous isatuximab in RVd induction for newly diagnosed multiple myeloma
These studies are conducted at HELIOS Klinikum Duisburg GmbH, reflecting the site’s commitment to improving outcomes for patients with hematologic cancers.
Neoplasms
Research in solid tumours focuses on extending overall and disease‑free survival through novel agents and optimized peri‑operative regimens.
- Lurbinectedin alone or combined with irinotecan for relapsed small‑cell lung cancer
- Pre‑operative FOLFOX versus risk‑adapted post‑surgical chemotherapy for locally advanced rectal cancer
- Evaluation of new maintenance approaches to delay progression in high‑risk solid tumours
The trials aim to determine whether these strategies can meaningfully improve survival for patients treated at the Duisburg site.
Parasitic Diseases
A focused study is assessing a higher‑strength topical therapy to enhance treatment outcomes for a common skin infestation.
- Comparison of 10% versus 5% permethrin cream for the management of scabies
- Safety and efficacy evaluation of the stronger formulation in everyday clinical practice
Conducted at HELIOS Klinikum Duisburg GmbH, this trial seeks to establish a more effective standard of care for affected patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Klinikum Duisburg GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Celgene Corp. | Phase IV | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isatuximab | 3 | Unknown | 2018-10-18 | 2024-04-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.